- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
3D MRI for Quantitative Brain Imaging Gets FDA Nod
SyMRI 3D reportedly combines precise estimates of regional brain volume with improved resolution bolstering accuracy with lesion analysis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for SyMRI 3D, a modality that may offer enhanced resolution and accuracy for brain magnetic resonance imaging (MRI) scans.
Combining quantitative MRI technology with isotropic resolution, SyMRI 3D provides improved accuracy in brain lesion analysis and facilitates brain structure and function assessments through precise brain region volume estimates, according to SyntheticMR U.S., the developer of the SyMRI 3D modality.
The newly FDA-cleared SyMRI 3D reportedly provides improved resolution that enhances accuracy of brain lesion analysis and better precision of brain region volume estimates, according to SyntheticMR U.S., the developer of the modality. (Image courtesy of SyntheticMR U.S.)
“Receiving 510(k) clearance for SyMRI 3D allows us to empower physicians to make more precise and informed decisions in diagnosis and treatment planning through quantitative imaging," said Jared Dixon, the president of SyntheticMR U.S.
SyMRI 3D will also be available to Philips customers as per a recently expanded partnership agreement between the two companies that was announced in November 2023.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
